SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- Jagpreet Chhatwal, PhD, presented two studies at the annual meeting of the American Association for the Study of Liver Diseases that addressed the burden of hepatitis C virus (HCV) and the cost of treating patients with the disease. The second generation of direct-acting antivirals (DAAs) that are currently used to treat patients with HCV were approved in 2013 and have achieved an almost universal cure rate. As Dr. Chhatwal states in one of his abstracts, the high price of these DAAs has been criticized by patients and payers. He also describes the field of HCV as very dynamic in terms of screening policy, availability of therapies, and...
↧